Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Conclusively, this study shed lights on the role of c-Myc oncoprotein in acute leukemia cells sensitivity to PI3K inhibitor and outlined that the combination of c-Myc inhibitor and CAL-101 may be a promising therapeutic approach in leukemia. 31412710 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells. 31255635 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. 30457982 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE BTK and PI3Kδ play crucial roles in the progression of leukemia, and studies confirmed that the dual inhibition against BTK and PI3Kδ could provide superior anticancer agents to single targeted therapies. 30605829 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia. 31688198 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In brief, 16b possessed of the potency for the further optimization as anti-leukemia drugs by inhibiting simultaneously Btk kinase and PI3Kδ kinase. 30077608 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Acute lymphoblastic leukemia (ALL) samples exhibit an activated PI3K/Akt pathway, which suggests a general role of Akt in the development of leukemia. 29179029 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Our study reveals a novel role for RhoA/ROCK1/PTEN/PI3K/Akt signaling in the regulation of mitochondrial translocation of cofilin and apoptosis and suggests MC-3129 as a potential drug for the treatment of human leukemia. 29844397 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE The Proviral Integration site of Moloney murine leukemia virus (PIM) serine/threonine protein kinases are overexpressed in many hematologic and solid tumor malignancies and play central roles in intracellular signaling networks important in tumorigenesis, including the Janus kinase-signal transducer and activator of transcription (JAK/STAT) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways. 29927999 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Interestingly, recent research has linked the PIM kinases to the PI3K/AKT/mTOR pathway in several types of cancers, but their connection in ovarian cancer has not been studied yet. 29401696 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Intrigued by the constant activation of PI3K in leukemia, this study aimed to investigate the effects of BKM120, as the excelled member of pan PI3K inhibitors, in a panel of hematologic malignant cell lines. 28834761 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway has been observed in different types of leukemia, including CML, acute myeloid leukemia, and acute lymphoblastic leukemia. 27018341 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Taken together, these results reveal an unrecognized function of MTE in inhibiting the proliferation and inducing the apoptosis of T-ALL cells, and identify a pathway of PTEN/PI3K/AKT/mTOR for the effects of MTE on leukemia therapy. 27756877 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE We show that mouse thymic stromal lymphopoietin does not stimulate the downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) activated by the human cytokine in primary high-risk leukemia with overexpression of the receptor component. 26611474 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Using, human leukemia HL-60 cells as a model, we for the first time report that CBA decreased expression of PI3K p110α, p85α, and pAKT in HL-60. 26013878 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Additionally, synergistic administration of PI3K/mTOR and JAK inhibitors further abrogated leukemia development. 26974155 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In the present study, we have shown for the first time that HBA decreased the expression of phosphotidylinositol-3 kinase (PI3K) p110α and p85α and caused significant downregulation of pAKT and of NFκB using human leukemia and breast cancer cells as in vitro models. 25299784 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. 24569456 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. 24100660 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE UA could induce the differentiation of U937 cells by activating the PI3K/Akt pathway, and it could be a potential candidate as a differentiation-inducing agent for the therapy of leukemia. 24484591 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia. 23334668 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE In addition, TrkC enhances the survival and proliferation of leukemia, which is correlated with activation of the PI3K/Akt pathway. 23832765 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE These findings highlight MDM2 as a potential therapeutic target to increase TKI-mediated apoptosis and imply that the combination of PI3K/mTOR inhibitor and TKI might form a novel strategy to combat TKI-resistant BCR-ABL1 positive leukemia. 24349524 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Flk1(+)CD31(-)CD34(-) MSCs that express BCR/ABL leukemia oncogene are CSCs of CML and they play a critical role in the progression of CML through PI3K/Akt/NF-κB/MMP-9/s-ICAM-1/s-KitL signaling pathway beyond HSCs. 23180012 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE These data provide a molecular rationale for using BH3 mimetics in combination with PI3K inhibitors to treat leukemia, especially in the case of an oncogenic signaling refractory to Tyrosine Kinase inhibitors. 23145067 2012